Apoptosis

Apoptosis is an autonomous, genetically controlled, orderly death of cells to maintain the stability of the internal environment. Unlike necrosis, apoptosis is not a passive process, but an active one, involving the activation, expression and regulation of a series of genes, and it is not a phenomenon of autologous damage under pathological conditions, but an active death process for better adaptation to the survival environment. Apoptosis is a fundamental biological phenomenon of cells and plays a necessary role in the removal of unwanted or abnormal cells in multicellular organisms. It plays an important role in the evolution of organisms, the stability of the internal environment, and the development of several systems. Apoptosis is not only a specific type of cell death, but also has important biological significance and complex molecular biological mechanisms.

Cat. No.	Product name
BP10141	GSK1838705A
BP10141	GSK1838705A is an effective IGF-1R inhibitor (IC50: 2.0 nM), modestly potent to IR (IC50: 1.6 nM) and ALK (IC50: 0.5 nM), respectively, and little inhibition to other protein kinases.
BP10116	GSK1904529A
BP10116	GSK1904529A is a specific inhibitor of IGF-1R (IC50=27 nM) and IR(IC50=25 nM) .
BP10253	GSK2256098
BP10253	GSK-2256098 is a small molecule FAK kinase inhibitor.
BP10385	GSK2593074A
BP10385	GSK2593074A is a necroptosis inhibitor for dual-targeting to both RIP1 and RIP3.
BP10386	GSK2606414
BP10386	GSK2606414 is an oral-available and specific PERK inhibitor (IC50=0.4 nM).
BP10387	GSK2656157
BP10387	GSK2656157 is a highly specific and ATP-competitive PERK inhibitor (IC50: 0.9 nM) in a cell-free assay. The selectivty is 500-fold higher against a panel of 300 kinases.
BP10484	GSK2795039
BP10484	GSK2795039 inhibits reactive oxygen species (ROS) production and NADPH consumption. GSK2795039 decreases apoptosis. GSK2795039 is an inhibitor of NADPH oxidase 2 (NOX2) (pIC50: 6 in different cell-free assays).
BP10684	GSK2801
BP10684	GSK2801 is an effective, specific and cell active acetyl-lysine competitive inhibitor of BAZ2A(Kd: 136 nM) and BAZ2B(Kd: 257 nM) bromodomains.
BP10685	GSK2982772
BP10685	GSK2982772 is an inhibitor of receptor interacting serine/threonine kinase 1 (RIPK1)with IC50 values of 16 nM and 20 nM for human and monkey RIP1, respectively.
BP10506	GSK2983559 active metabolite
BP10506	GSK 2983559 (RIP2 kinase inhibitor 1) is a potent, selective receptor-interacting protein-2 (RIP2) kinase inhibitor.
BP10658	GSK2983559 free acid
BP10658	GSK2983559 free acid is an effective and selective inhibitor of receptor-interacting protein 2 (RIP2). GSK2983559 free acid shows excellent activity in blocking many proinflammatory cytokine responses in human inflammatory bowel disease explant samples an
BP10686	GSK3145095
BP10686	GSK3145095 is an orally active inhibitor of RIPK1 with IC50 of 5 nM, with potential immunomodulatory activities and antineoplastic.
BP10695	GSK3179106
BP10695	GSK3179106 is RET kinase inhibitor with an IC50 of 0.4 nM
BP10687	GSK481
BP10687	GSK481 is a RIP1(Receptor Interacting Protein Kinase1) inhibitor. Inhibition of RIP1 has been shown to hinder cell necrotic death.
BP10401	GSK583
BP10401	GSK583 is a highly effective and specific RIP2 kinase inhibitor (IC50: 5 nM).
BP10402	GSK621
BP10402	GSK621 is a specific and potent AMPK activator.
BP10667	GSK-843
BP10667	GSK-843 is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor ( IC50: 8.6 nM for binding RIP3 kinase domain; IC50: 6.5 nM for inhibiting kinase activity).
BP10400	GSK-872
BP10400	GSK872 (GSK2399872A) is an effective and specific RIP3 kinase inhibitor. It binds RIP3 kinase domain with high affinity (IC50: 1.8 nM) and inhibits kinase activity (IC50: 1.3 nM).
BP10115	GSK-923295
BP10115	GSK923295 is a selective allosteric inhibitor of CENP-E kinesin motor ATPase(Ki=3.2 nM).
BP10945	GSK963
BP10945	GSK963 (Racemate), a structurally distinct, potent and selective inhibitor of RIP1 kinase(IC50=29 nM).